Neptune Generics, LLC et al. vs. Aventis Pharma S.A. et al.
Explore the PTAB proceeding IPR2019-00136 filed by Neptune Generics, LLC et al. on 2018-10-31. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.
Proceeding Overview
Proceeding Number
IPR2019-00136
Filing Date
2018-10-31
Accorded Filing Date
2018-10-31
Institution Decision Date
2019-05-06
Last Modified Date
2022-10-10
Proceeding Type
IPR
Termination Date
β
Trial Status
Institution Denied
Parties & Counsel
Petitioner
Neptune Generics, LLC et al.
Represented By
Gasser, Alexanderet alPatent Owner / Respondent
Aventis Pharma S.A. et al.
Represented By
Minion, Danielet alPatent Information
Tribunal & APJ Panel Intelligence
Tribunal
Patent Trial and Appeal Board (USPTO)
Technology Center
TC 1600 - Biotechnology & Organic Chemistry
Decisions Rendered
1 Total
Proceeding Status
Institution Denied
Administrative Patent Judges (APJ Panel)
Board Decisions & Rulings (1)
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 9 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 5,847,170 Asserted | Asserted Patent | View Official Patent → |
| πΊπΈ United States | US 6,331,635 B1 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 6,372,780 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 6,387,946 B1 | US Continuation / Sibling | View Official Patent → |
| π«π· France | FR 9503545 A | France Counterpart | View Official Patent → |
| π«π· France | FR 2732340 B1 | France Counterpart | View Official Patent → |
| π«π· France | FR 9515381 A | France Counterpart | View Official Patent → |
| π«π· France | FR 2742754 B1 | France Counterpart | View Official Patent → |
| πΊπΈ United States | US 1,014,496 P | US Continuation / Sibling | View Official Patent → |
Mylan Laboratories Limited et al. v. Aventis Pharma S.A. et al.